Private Advisor Group LLC lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.6% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 80,809 shares of the biopharmaceutical company’s stock after purchasing an additional 1,268 shares during the period. Private Advisor Group LLC’s holdings in Gilead Sciences were worth $5,600,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also made changes to their positions in the company. Harel Insurance Investments & Financial Services Ltd. increased its position in shares of Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after acquiring an additional 1,400 shares in the last quarter. Penserra Capital Management LLC increased its position in shares of Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 144 shares in the last quarter. American Beacon Advisors Inc. purchased a new position in shares of Gilead Sciences in the first quarter worth approximately $143,000. Sterling Investment Advisors Ltd. purchased a new position in shares of Gilead Sciences in the second quarter worth approximately $184,000. Finally, Truepoint Inc. purchased a new position in shares of Gilead Sciences in the second quarter worth approximately $204,000. 74.62% of the stock is currently owned by institutional investors.
In related news, EVP Gregg H. Alton sold 25,000 shares of the company’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $83.05, for a total transaction of $2,076,250.00. Following the transaction, the executive vice president now owns 101,488 shares in the company, valued at approximately $8,428,578.40. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the transaction, the executive vice president now owns 77,363 shares in the company, valued at approximately $5,788,299.66. The disclosure for this sale can be found here. In the last ninety days, insiders sold 446,819 shares of company stock worth $36,269,486. 1.30% of the stock is owned by insiders.
Several research analysts have recently weighed in on GILD shares. BMO Capital Markets reissued a “hold” rating and issued a $82.00 target price on shares of Gilead Sciences in a research report on Friday, October 20th. J P Morgan Chase & Co set a $85.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday, October 25th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Monday, August 28th. Vetr raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $89.27 price objective on the stock in a research report on Wednesday, September 6th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and set a $83.00 price objective (up from $77.00) on shares of Gilead Sciences in a research report on Friday, October 6th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $84.87.
Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at $71.15 on Wednesday. The stock has a market cap of $92,920.00, a price-to-earnings ratio of 7.60, a price-to-earnings-growth ratio of -1.22 and a beta of 1.13. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a fifty-two week low of $63.76 and a fifty-two week high of $86.27.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. During the same quarter in the prior year, the firm earned $2.75 EPS. The firm’s quarterly revenue was down 13.2% compared to the same quarter last year. equities research analysts forecast that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 2.92%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s payout ratio is 23.66%.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.